Antineoplastic agent-associated serpentine supravenous hyperpigmentation: Superficial venous system hyperpigmentation following intravenous chemotherapy

Southern Medical Journal

Volumn 103, Issue 3, 2010, Pages 231-235

  Geddes, Elizabeth R C ^a   Cohen, Philip R ^a  

^a NONE

Author keywords

Chemotherapy; Fluorouracil; Hyperpigmentation; Serpentine; Supravenous

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOTEMUSTINE; NAVELBINE; PACLITAXEL; PREDNISOLONE; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOCYTIC LEUKEMIA; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL FEATURE; COLON CANCER; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HYPERPIGMENTATION; HYPOPHARYNX CANCER; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LUNG SQUAMOUS CELL CARCINOMA; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PROSTATE CANCER; RECTUM CANCER; REVIEW; RHABDOMYOSARCOMA; SERPENTINE SUPRAVENOUS HYPERPIGMENTATION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; VENOUS CIRCULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUOROURACIL; HUMANS; HYPERPIGMENTATION; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; VEINS;

EID: 77949344464     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181ce0f5e     Document Type: Review

References (31)

1. Vukelja SJ, Bonner MW, McCollough M, et al. Unusual serpentine hyperpigmentation associated with 5-fluorouracil: case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol 1991;25:905-908.
2. Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962;74:229-236.
3. Pujol RM, Rocamora V, Lopez-Pousa A, et al. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 1998;39:839-842.
4. Hrushesky WJ. Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis 1980;26:181-182.
5. Hrushesky WJ. Serpentine supravenous fluorouracil hyperpigmentation [letter]. JAMA 1976;236:138.
6. Hrushesky WJ. Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation [letter]. Cancer Treat Rep 1976;60:639.
7. Moertel CG, Reitemeier RJ, Hahn RG. Therapy with the Fluorinated Pyrimidines, Chapter 13. in Moertel CG, Adson MA, Reitemeier RJ, (eds): Advanced Gastrointestinal Cancer, Clinical Management and Chemotherapy. New York, NY: Paul B Hoebner Inc., 1969, pp 86-107.
8. Aydogan I, Kavak A, Parlak AH, et al. Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel. J Eur Acad Dermatol Venereol 2005;19:345-347.
9. Marcoux D, Anex R, Russo P. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 2000;43:540-546.
10. Mataix J, Betlloch I, Palmero F, et al. Persistent supravenous eruption induced by intravenous bortezomib therapy. Br J Dermatol 2008;158: 863-864.
11. Marongiu P, Lissia A, Cottoni F. Chemotherapy-induced persistent serpentine supra-venous hyperpigmented eruption and persistent supra-venous erythematous eruption: case report. G Ital Dermatol Venereol 2009; 144:97-100.
12. Schulte-Huermann P, Zumdick M, Ruzicka T. Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)- positive anaplastic large-cell lymphoma. Dermatology 1995;191:65-67.
13. Lang K, Groeger M, Neumann NJ, et al. Supravenous hyperpigmentation, transverse leuconychia and transverse melanonychia after chemotherapy for Hodgkin's disease. J Eur Acad Dermatol Venereol 2002;16: 162-163.
14. Baselga E, Drolet BA, Casper J, et al. Chemotherapy-associated supravenous hyperpigmentation. Dermatology 1996;192:384-385.
15. Cecchi R, Tuci F, Giomi A, et al. Supravenous hyperpigmentation induced by vinorelbine [letter]. Dermatology 1994;188:244.
16. Claudy AL, Lévigne V, Boucheron S. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine. Dermatology 1992; 184:70-72.
17. Schrijvers D, Van Den Brande J, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 142;1069-1070.
18. Arias D, Requena L, Hasson A, et al. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. J Cutan Pathol 1991;18:344-346.
19. Spencer HJ. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. J Surg Oncol 1984;26: 47-50.
20. Fine JD, Breathnach SM. Distinctive eruption characterized by linear supravenous papules and erythroderma following broxuridine (bromodeoxyuridine) therapy and radiotherapy. Arch Dermatol 1986;122:199-200.
21. Chen GY, Lee JY, Chen WC. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma. Br J Dermatol 2005;152:1383-1385.
22. Cohen PR. Cancer Chemotherapy-Associated Mucocutaneous Reactions. Chapter 39. in Pazdur R (ed): Medical Oncology: A Comprehensive Review. New York, NY, PRR, 1993, pp 493-500.
23. Hum GJ, Bateman JR. 5-day iv infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy. Cancer Chemother Rep 1975;59:1171-1179.
24. Jain V, Bhandary S, Prasad GN, et al. Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 2005;53:529-530.
25. Jogi R, Garman M, Pielop J, et al. Reticulate hyperpigmentation secondary to 5-fluorouracil and idarubicin. J Drugs Dermatol 2005;4:652-656.
26. Allen BJ, Parker D, Wright AL. Reticulate pigmentation due to 5-fluorouracil. Int J Dermatol 1995;34:219-220.
27. Cohen PR, Zalar GL. Cutis marmorata telangiectatica congenita: clinicopathologic characteristics and differential diagnosis. Cutis 1988;42: 518-522.
28. Riahi RR, Cohen PR, Robinson FW, et al. Erythema ab igne mimicking livedo reticularis. Int J Dermatol in press.
29. Herrero C, Gullabert A, Mascaro-Galy JM. Diagnosis and treatment of livedo reticularis on the legs. Actas Dermosifillogr 2008;99:598-607.
30. Schallreuter KU, Ring J. A probable mechanism for hyperpigmentation by fotemustine [letter]. Dermatology 1992;185:76.
31. Werth VP, Schumacher HR Jr, Von Feldt JM. Linear hyperpigmentation overlying veins in association with collagen vascular disease. J Am Acad Dermatol 1993;29:1039-1040.